{"totalCount":2,"studies":[
{"protocolSection":{"identificationModule":{"nctId":"NCT05747924","orgStudyIdInfo":{"id":"AOC 1020-CS1"},"organization":{"fullName":"Avidity Biosciences, Inc.","class":"INDUSTRY"},"briefTitle":"Phase 1/2 Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)","officialTitle":"A Randomized, Double-blind, Placebo-controlled, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of AOC 1020 Administered Intravenously to Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)","acronym":"FORTITUDE"},"statusModule":{"statusVerifiedDate":"2025-03","overallStatus":"ACTIVE_NOT_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2023-04-04","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2026-10","type":"ESTIMATED"},"completionDateStruct":{"date":"2027-04","type":"ESTIMATED"},"studyFirstSubmitDate":"2023-02-17","studyFirstSubmitQcDate":"2023-02-27","studyFirstPostDateStruct":{"date":"2023-02-28","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-03-31","lastUpdatePostDateStruct":{"date":"2025-04-01","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Avidity Biosciences, Inc.","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"A Randomized, Double-blind, Placebo-controlled, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of AOC 1020 Administered Intravenously to Participants with Facioscapulohumeral Muscular Dystrophy (FSHD)","detailedDescription":"AOC 1020-CS1 is a first-in-human, 3-part, multi-center, Phase 1/2, randomized, double-blind, placebo-controlled study designed to evaluate safety, tolerability, pharmacokinetics and to explore pharmacodynamics and efficacy of single and multiple-doses of AOC 1020 administered intravenously in participants with FSHD Type 1 (FSHD1) and FSHD Type 2 (FSHD2).\n\nCohort A comprises a placebo-controlled dose titration cohort (Cohort A1) which includes a nested single and multiple dose schedule. Cohort B comprises a placebo-controlled, nested single ascending dose (SAD)/multiple ascending dose (MAD) cohort (Cohort B1). Cohort C comprises a randomized, placebo-controlled, expansion cohort (Cohort C1). For each of Cohorts A, B, and C the study duration is 12 months as the active treatment period is approximately 9 months for Cohorts A \\& B and approximately 10 months for Cohort C followed by a 12-week follow-up period for Cohorts A \\& B and a 7-week follow-up period for Cohort C. Once participants have completed active treatment with follow-up through 12 months, they may have the option to participate in a planned open-label extension. If patients do not enroll in the open-label extension, they will be followed for 12-weeks after their last dose of study medication."},"conditionsModule":{"conditions":["FSHD","FSHD1","FSHD2","FMD","FMD2","Fascioscapulohumeral Muscular Dystrophy","Fascioscapulohumeral Muscular Dystrophy Type 1","Fascioscapulohumeral Muscular Dystrophy Type 2","Dystrophies, Facioscapulohumeral Muscular","Dystrophy, Facioscapulohumeral Muscular","Facioscapulohumeral Muscular Dystrophy 1","Facioscapulohumeral Muscular Dystrophy 2","Facio-Scapulo-Humeral Dystrophy","Atrophy, Facioscapulohumeral","Atrophies, Facioscapulohumeral","Facioscapulohumeral Atrophy","Muscular Dystrophies","Muscular Dystrophy, Facioscapulohumeral","FSH Muscular Dystrophy","Landouzy Dejerine Dystrophy","Landouzy-Dejerine Muscular Dystrophy","Dystrophies, Landouzy-Dejerine","Dystrophy, Landouzy-Dejerine","Landouzy-Dejerine Syndrome","Muscular Dystrophy, Landouzy Dejerine","Progressive Muscular Dystrophy","FSH"],"keywords":["FORTITUDE","Avidity","Avidity Biosciences","AOC 1020"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1","PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"SEQUENTIAL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":90,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"AOC 1020 Regimen 1","type":"EXPERIMENTAL","description":"Cohort A: AOC 1020 Dose Regimen 1; Five doses administered intravenously over 9 months","interventionNames":["Drug: AOC 1020"]},{"label":"AOC 1020 Regimen 2","type":"EXPERIMENTAL","description":"Cohort B1: AOC 1020 Dose Regimen 2; Five doses administered intravenously over 9 months","interventionNames":["Drug: AOC 1020"]},{"label":"AOC 1020 Regimen 3","type":"EXPERIMENTAL","description":"Cohort C: AOC 1020 Dose Regimen 3; Eight doses administered intravenously over approximately 10 months","interventionNames":["Drug: AOC 1020"]},{"label":"Placebo (Saline) Regimen 1","type":"PLACEBO_COMPARATOR","description":"Cohort A \\& B: Placebo; Five doses administered intravenously over 9 months","interventionNames":["Drug: Placebo"]},{"label":"Placebo (Saline) Regimen 2","type":"PLACEBO_COMPARATOR","description":"Cohort C: Placebo; Eight doses administered intravenously over approximately 10 months","interventionNames":["Drug: Placebo"]}],"interventions":[{"type":"DRUG","name":"AOC 1020","description":"AOC 1020 will be administered via intravenous (IV) infusion","armGroupLabels":["AOC 1020 Regimen 1","AOC 1020 Regimen 2","AOC 1020 Regimen 3"]},{"type":"DRUG","name":"Placebo","description":"Placebo will be administered via intravenous (IV) infusion","armGroupLabels":["Placebo (Saline) Regimen 1","Placebo (Saline) Regimen 2"],"otherNames":["Saline"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Incidence of treatment-emergent adverse events (Cohorts A & B)","timeFrame":"Through study completion, up to Day 365"},{"measure":"Change in DUX4-regulated gene expression in muscle biopsies (Cohort C)","timeFrame":"Day 120"},{"measure":"Change in a circulating biomarker of FSHD disease biology (Cohort C)","timeFrame":"Day 120"}],"secondaryOutcomes":[{"measure":"Plasma pharmacokinetic (PK) parameters of AOC 1020 (Cohorts A & B)","description":"Observed maximum concentration","timeFrame":"Through study completion; up to Day 365"},{"measure":"Plasma pharmacokinetic (PK) parameters of AOC 1020 (Cohorts A & B)","description":"Observed half-life","timeFrame":"Through study completion; up to Day 365"},{"measure":"Plasma pharmacokinetic (PK) parameters of AOC 1020 (Cohorts A & B)","description":"Observed area under the curve","timeFrame":"Through study completion; up to Day 365"},{"measure":"Muscle drug concentration (Cohorts A, B & C)","description":"Concentration of siRNA component in skeletal muscle","timeFrame":"Day 120"},{"measure":"Change in DUX4-regulated gene expression in muscle biopsies (Cohort C)","timeFrame":"Day 120"},{"measure":"% Change in circulating creatine kinase (Cohort C)","timeFrame":"Through study completion; up to Day 365"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* FSHD1 or FSHD2 diagnosis confirmed by documented genetic testing (testing provided by Sponsor)\n* Ambulatory and able to walk 10 meters (with or without assistive devices such as one cane, walking stick or braces)\n* At least 1 muscle region suitable for biopsy (testing provided by Sponsor)\n* Muscle weakness in both upper and lower body, as determined by Investigator\n\nExclusion Criteria:\n\n* Pregnant or intends to become pregnant while on study, or active breastfeeding\n* Unwilling or unable to continue to comply with contraceptive requirements\n* Body mass index (BMI) \\>35.0 kg/m2 at Screening\n* History of muscle biopsy within 30 days of the screening biopsy or planning to undergo any nonstudy muscle biopsies over the duration of the study\n* History of bleeding disorders, significant keloid, or other skin or muscle conditions (e.g., severe muscle wasting) that, in the opinion of the Investigator, makes the participant unsuitable for serial muscle biopsy\n* Anticipated survival less than 2 years\n* Blood or plasma donation within 16 weeks of Study Day 1\n* Any contraindication to MRI\n* Any abnormal lab values, conditions or diseases that, in the opinion of the investigator or Sponsor, would make the participant unsuitable for the study or could interfere with participation or completion of the study\n* Treatment with any investigative medication within 1 month (or 5 half-lives of the drug, whichever is longer) of Screening","healthyVolunteers":false,"sex":"ALL","minimumAge":"16 Years","maximumAge":"70 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"locations":[{"facility":"University of California Los Angeles","city":"Los Angeles","state":"California","zip":"90095","country":"United States","geoPoint":{"lat":34.05223,"lon":-118.24368}},{"facility":"Stanford University","city":"Palo Alto","state":"California","zip":"94304","country":"United States","geoPoint":{"lat":37.44188,"lon":-122.14302}},{"facility":"University of California San Diego","city":"San Diego","state":"California","zip":"92093","country":"United States","geoPoint":{"lat":32.71571,"lon":-117.16472}},{"facility":"University of Colorado","city":"Denver","state":"Colorado","zip":"80045","country":"United States","geoPoint":{"lat":39.73915,"lon":-104.9847}},{"facility":"University of Florida","city":"Gainesville","state":"Florida","zip":"32608","country":"United States","geoPoint":{"lat":29.65163,"lon":-82.32483}},{"facility":"Rare Disease Research","city":"Atlanta","state":"Georgia","zip":"30329","country":"United States","geoPoint":{"lat":33.749,"lon":-84.38798}},{"facility":"Kansas University Medical Center","city":"Kansas City","state":"Kansas","zip":"66205","country":"United States","geoPoint":{"lat":39.11417,"lon":-94.62746}},{"facility":"University of Rochester Medical Center","city":"Rochester","state":"New York","zip":"14642","country":"United States","geoPoint":{"lat":43.15478,"lon":-77.61556}},{"facility":"Duke University","city":"Durham","state":"North Carolina","zip":"27708","country":"United States","geoPoint":{"lat":35.99403,"lon":-78.89862}},{"facility":"Ohio State University","city":"Columbus","state":"Ohio","zip":"43221","country":"United States","geoPoint":{"lat":39.96118,"lon":-82.99879}},{"facility":"University of Pennsylvania","city":"Philadelphia","state":"Pennsylvania","zip":"19104","country":"United States","geoPoint":{"lat":39.95238,"lon":-75.16362}},{"facility":"University of Texas Southwestern","city":"Dallas","state":"Texas","zip":"75390","country":"United States","geoPoint":{"lat":32.78306,"lon":-96.80667}},{"facility":"Virginia Commonwealth University","city":"Richmond","state":"Virginia","zip":"23298","country":"United States","geoPoint":{"lat":37.55376,"lon":-77.46026}},{"facility":"University of Washington","city":"Seattle","state":"Washington","zip":"98104","country":"United States","geoPoint":{"lat":47.60621,"lon":-122.33207}},{"facility":"University of Ottawa","city":"Ottawa","state":"Ontario","zip":"K1Y 4E9","country":"Canada","geoPoint":{"lat":45.41117,"lon":-75.69812}},{"facility":"University College London","city":"London","zip":"WIT 7HA","country":"United Kingdom","geoPoint":{"lat":51.50853,"lon":-0.12574}},{"facility":"University of Sheffield","city":"Sheffield","zip":"S10 2TN","country":"United Kingdom","geoPoint":{"lat":53.38297,"lon":-1.4659}}]},"referencesModule":{"seeAlsoLinks":[{"label":"Avidity Biosciences Website","url":"https://www.aviditybiosciences.com/"},{"label":"FORTITUDE Study Website","url":"https://fortitude-study.com/"}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-25","removedCountries":["Netherlands"]},"conditionBrowseModule":{"meshes":[{"id":"D020391","term":"Muscular Dystrophy, Facioscapulohumeral"},{"id":"C563557","term":"Facioscapulohumeral Muscular Dystrophy 1B"},{"id":"D009136","term":"Muscular Dystrophies"},{"id":"C536391","term":"Facioscapulohumeral muscular dystrophy 1a"}],"ancestors":[{"id":"D020966","term":"Muscular Disorders, Atrophic"},{"id":"D009135","term":"Muscular Diseases"},{"id":"D009140","term":"Musculoskeletal Diseases"},{"id":"D009468","term":"Neuromuscular Diseases"},{"id":"D009422","term":"Nervous System Diseases"},{"id":"D030342","term":"Genetic Diseases, Inborn"},{"id":"D009358","term":"Congenital, Hereditary, and Neonatal Diseases and Abnormalities"}]},"interventionBrowseModule":{"meshes":[{"id":"D012965","term":"Sodium Chloride"}],"ancestors":[{"id":"D002712","term":"Chlorides"},{"id":"D006851","term":"Hydrochloric Acid"},{"id":"D017606","term":"Chlorine Compounds"},{"id":"D007287","term":"Inorganic Chemicals"},{"id":"D017670","term":"Sodium Compounds"}]}},"hasResults":false},
{"protocolSection":{"identificationModule":{"nctId":"NCT06411288","orgStudyIdInfo":{"id":"AOC 1001-CS3"},"organization":{"fullName":"Avidity Biosciences, Inc.","class":"INDUSTRY"},"briefTitle":"Global Study of Del-desiran for the Treatment of DM1","officialTitle":"A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Global Study to Evaluate the Efficacy and Safety of Intravenous AOC 1001 for the Treatment of Myotonic Dystrophy Type 1","acronym":"HARBOR"},"statusModule":{"statusVerifiedDate":"2026-01","overallStatus":"ACTIVE_NOT_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2024-05-30","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2026-08","type":"ESTIMATED"},"completionDateStruct":{"date":"2026-09","type":"ESTIMATED"},"studyFirstSubmitDate":"2024-05-08","studyFirstSubmitQcDate":"2024-05-08","studyFirstPostDateStruct":{"date":"2024-05-13","type":"ACTUAL"},"lastUpdateSubmitDate":"2026-01-20","lastUpdatePostDateStruct":{"date":"2026-01-22","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Avidity Biosciences, Inc.","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Global Study to Evaluate the Efficacy and Safety of Intravenous Delpacibart Etedesiran (abbreviated del-desiran, formerly AOC 1001) for the Treatment of Myotonic Dystrophy Type 1","detailedDescription":"The study consists of a Screening Period of up to 6 weeks and 54-week Treatment Period. The anticipated duration is approximately 60 weeks.\n\nParticipants will be randomized to receive an intravenous infusion of either del-desiran or placebo at the clinical study site every 8 weeks for a total of 7 doses. The final dose will occur at Week 48, followed by a final assessment at Week 54.\n\nAfter completion of Week 54 assessments, eligible participants will have the option to enroll into an open label extension (OLE) study, pending regulatory approval.\n\nAn Independent Data Monitoring Committee (IDMC) comprised of members independent and external to the Sponsor will review safety, tolerability, and efficacy (as needed) data of this study at regular intervals."},"conditionsModule":{"conditions":["DM1","Myotonic Dystrophy","Myotonic Dystrophy 1","Myotonia","Myotonic Dystrophy Type 1 (DM1)","Dystrophy Myotonic","Myotonic Disorders","Steinert Disease","Steinert","Myotonic Muscular Dystrophy"],"keywords":["DM1","Myotonic Dystrophy","Myotonic Dystrophy 1","Myotonia","Myotonic Dystrophy Type 1 (DM1)","Dystrophy Myotonic","Myotonic Disorders","Steinert Disease","Steinert","Myotonic Muscular Dystrophy","HARBOR","Avidity Biosciences","Avidity","AOC 1001","Del-desiran","Delpacibart etedesiran"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":159,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Del-desiran","type":"EXPERIMENTAL","description":"Del-desiran (AOC 1001) will be administered seven times","interventionNames":["Drug: AOC 1001 (del-desiran)"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","description":"Saline will be administered seven times","interventionNames":["Drug: Placebo"]}],"interventions":[{"type":"DRUG","name":"AOC 1001 (del-desiran)","description":"Del-desiran will be administered by intravenous (IV) infusion.","armGroupLabels":["Del-desiran"]},{"type":"DRUG","name":"Placebo","description":"Placebo will be administered by intravenous (IV) infusion.","armGroupLabels":["Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Hand function","description":"video Hand Opening Time (vHOT)","timeFrame":"Through Week 54"}],"secondaryOutcomes":[{"measure":"Hand grip strength","description":"by dynamometer","timeFrame":"Through Week 54"},{"measure":"Quantitative Muscle Testing composite score","description":"by dynamometer","timeFrame":"Through Week 54"},{"measure":"Myotonic Dystrophy Type 1 activity and participation scale c","timeFrame":"Through Week 54"},{"measure":"10-Meter Walk/Run Test","description":"Time (in seconds) to walk or run 10 meters","timeFrame":"Through Week 54"}]},"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n* Clinical and genetic diagnosis (CTG repeat â‰¥ 100) of DM1\n* Ability to walk independently (orthoses and ankle braces allowed) for at least 10 meters at screening\n\nKey Exclusion Criteria:\n\n* Breastfeeding, pregnancy, or intent to become pregnant during the study\n* Unwilling or unable to comply with contraceptive requirements\n* Abnormal lab values, conditions or diseases that would make the participant unsuitable for the study\n* Diabetes that is not adequately controlled\n* History of decompensated heart failure within 3 months of screening. Participants with preexisting pacemaker/ICD are not excluded.\n* Body Mass Index \\> 35 kg/m2 at Screening\n* Recently treated with an investigational drug or biological agent\n* Treatment with anti-myotonic medication within 5 half-lives or 14 days of baseline, whichever is longer, prior to baseline.\n\nNote: Additional protocol defined Inclusion and Exclusion criteria apply","healthyVolunteers":false,"sex":"ALL","minimumAge":"16 Years","maximumAge":"65 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"locations":[{"facility":"Stanford University","city":"Stanford","state":"California","zip":"94305","country":"United States","geoPoint":{"lat":37.42411,"lon":-122.16608}},{"facility":"University of Colorado","city":"Denver","state":"Colorado","zip":"80045","country":"United States","geoPoint":{"lat":39.73915,"lon":-104.9847}},{"facility":"University of Florida","city":"Gainesville","state":"Florida","zip":"32608","country":"United States","geoPoint":{"lat":29.65163,"lon":-82.32483}},{"facility":"University Research Center of South Florida","city":"Tampa","state":"Florida","zip":"33612","country":"United States","geoPoint":{"lat":27.94752,"lon":-82.45843}},{"facility":"Indiana University (IU)","city":"Indianapolis","state":"Indiana","zip":"46202","country":"United States","geoPoint":{"lat":39.76838,"lon":-86.15804}},{"facility":"Kansas University Medical Center","city":"Kansas City","state":"Kansas","zip":"66205","country":"United States","geoPoint":{"lat":39.11417,"lon":-94.62746}},{"facility":"Kennedy Krieger Institute","city":"Baltimore","state":"Maryland","zip":"21205","country":"United States","geoPoint":{"lat":39.29038,"lon":-76.61219}},{"facility":"Beth Israel Deaconess Medical Center","city":"Boston","state":"Massachusetts","zip":"02215","country":"United States","geoPoint":{"lat":42.35843,"lon":-71.05977}},{"facility":"University of Minnesota","city":"Minneapolis","state":"Minnesota","zip":"55455","country":"United States","geoPoint":{"lat":44.97997,"lon":-93.26384}},{"facility":"University of Rochester Medical Center","city":"Rochester","state":"New York","zip":"14642","country":"United States","geoPoint":{"lat":43.15478,"lon":-77.61556}},{"facility":"Duke University Medical Center","city":"Durham","state":"North Carolina","zip":"27708","country":"United States","geoPoint":{"lat":35.99403,"lon":-78.89862}},{"facility":"Wake Forest","city":"Winston-Salem","state":"North Carolina","zip":"27157","country":"United States","geoPoint":{"lat":36.09986,"lon":-80.24422}},{"facility":"University of Cincinnati Gardner Neuroscience Institute","city":"Cincinnati","state":"Ohio","zip":"45219","country":"United States","geoPoint":{"lat":39.12711,"lon":-84.51439}},{"facility":"Ohio State University","city":"Columbus","state":"Ohio","zip":"43221","country":"United States","geoPoint":{"lat":39.96118,"lon":-82.99879}},{"facility":"University of Pennsylvania","city":"Philadelphia","state":"Pennsylvania","zip":"19104","country":"United States","geoPoint":{"lat":39.95238,"lon":-75.16362}},{"facility":"Houston Methodist Neurological Institute","city":"Houston","state":"Texas","zip":"77030","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"facility":"Virginia Commonwealth University","city":"Richmond","state":"Virginia","zip":"23298","country":"United States","geoPoint":{"lat":37.55376,"lon":-77.46026}},{"facility":"University of Washington","city":"Seattle","state":"Washington","zip":"98104","country":"United States","geoPoint":{"lat":47.60621,"lon":-122.33207}},{"facility":"The Ottawa Hospital","city":"Ottawa","state":"Ontario","zip":"K1Y 4E9","country":"Canada","geoPoint":{"lat":45.41117,"lon":-75.69812}},{"facility":"Montreal Neurological Institute","city":"Montreal","state":"Quebec","zip":"H3A 2B4","country":"Canada","geoPoint":{"lat":45.50884,"lon":-73.58781}},{"facility":"Aarhus University Hospital","city":"Aarhus N","zip":"8200","country":"Denmark","geoPoint":{"lat":56.20367,"lon":10.17317}},{"facility":"Rigshospitalet","city":"Copenhagen","zip":"2100","country":"Denmark","geoPoint":{"lat":55.67594,"lon":12.56553}},{"facility":"AP-HP Hopital Pitie-Salpetriere","city":"Paris","zip":"75013","country":"France","geoPoint":{"lat":48.85341,"lon":2.3488}},{"facility":"Klinikum der Ludwig-Maximilians-Universitaet Muenchen","city":"Munich","zip":"80336","country":"Germany","geoPoint":{"lat":48.13743,"lon":11.57549}},{"facility":"Fondazione Serena Onlus - Centro Clinico NeMO Milano","city":"Milan","zip":"20162","country":"Italy","geoPoint":{"lat":42.78235,"lon":12.59836}},{"facility":"Aomori Hospital","city":"Aomori","state":"Aomori","zip":"038-1331","country":"Japan","geoPoint":{"lat":40.81667,"lon":140.73333}},{"facility":"National Hospital Organization Osaka Toneyama Medical Center","city":"Osaka","zip":"560-8552","country":"Japan","geoPoint":{"lat":34.69379,"lon":135.50107}},{"facility":"Osaka University Hospital","city":"Osaka","zip":"565-0871","country":"Japan","geoPoint":{"lat":34.69379,"lon":135.50107}},{"facility":"National Center of Neurology and Psychiatry","city":"Tokyo","zip":"187-8551","country":"Japan","geoPoint":{"lat":35.6895,"lon":139.69171}},{"facility":"Maastricht University Medical Center","city":"Maastricht","zip":"6229 HX","country":"Netherlands","geoPoint":{"lat":50.84833,"lon":5.68889}},{"facility":"Stichting Radboud Universitair Medisch Centrum","city":"Nijmegen","zip":"6525 GA","country":"Netherlands","geoPoint":{"lat":51.8425,"lon":5.85278}},{"facility":"Hospital Universitario Donostia","city":"Donostia / San Sebastian","zip":"20014","country":"Spain","geoPoint":{"lat":43.31283,"lon":-1.97499}},{"facility":"University College London Hospital","city":"London","zip":"NW1 2BU","country":"United Kingdom","geoPoint":{"lat":51.50853,"lon":-0.12574}},{"facility":"St. Georges University Hospitals NHS Foundation Trust","city":"London","zip":"SW17 0QT","country":"United Kingdom","geoPoint":{"lat":51.50853,"lon":-0.12574}}]},"ipdSharingStatementModule":{"ipdSharing":"UNDECIDED"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-25","removedCountries":["Ireland"]},"conditionBrowseModule":{"meshes":[{"id":"D009223","term":"Myotonic Dystrophy"},{"id":"D009222","term":"Myotonia"},{"id":"D020967","term":"Myotonic Disorders"}],"ancestors":[{"id":"D009136","term":"Muscular Dystrophies"},{"id":"D020966","term":"Muscular Disorders, Atrophic"},{"id":"D009135","term":"Muscular Diseases"},{"id":"D009140","term":"Musculoskeletal Diseases"},{"id":"D020271","term":"Heredodegenerative Disorders, Nervous System"},{"id":"D019636","term":"Neurodegenerative Diseases"},{"id":"D009422","term":"Nervous System Diseases"},{"id":"D009468","term":"Neuromuscular Diseases"},{"id":"D030342","term":"Genetic Diseases, Inborn"},{"id":"D009358","term":"Congenital, Hereditary, and Neonatal Diseases and Abnormalities"},{"id":"D020879","term":"Neuromuscular Manifestations"},{"id":"D009461","term":"Neurologic Manifestations"},{"id":"D012816","term":"Signs and Symptoms"},{"id":"D013568","term":"Pathological Conditions, Signs and Symptoms"}]}},"hasResults":false}
]}